[vc_row type=”vc_default” full_width_row=”true” bg_type=”bg_color” bg_override=”full” bg_color_value=”#f4f4f4″ css=”.vc_custom_1491338532055{margin-top: -70px !important;}”][vc_column][vc_custom_heading text=”PARTNER TRACE” font_container=”tag:h1|text_align:left|color:%23232323″ use_theme_fonts=”yes”][vc_custom_heading text=”P.I. FREDERIC AMANT” font_container=”tag:h2|text_align:left|color:%23606060″ use_theme_fonts=”yes”][vc_custom_heading text=”UNIVERSITY OF LEUVEN” font_container=”tag:h4|text_align:left|color:%238e8e8e” use_theme_fonts=”yes”][/vc_column][/vc_row][vc_row][vc_column width=”1/6″][vc_single_image image=”143″ img_size=”full” onclick=”custom_link” img_link_target=”_blank” image_hovers=”false” link=”http://www.uzleuven-kuleuven.be/lki/trace/trace-leuven-pdx-platform”][/vc_column][vc_column width=”2/3″][vc_column_text]

Trace is a multidisciplinary and multicenter patient-derived tumor xenograft (PDTX) platform, located at the KU Leuven – UZ Leuven Institute in Belgium. The platform aims to be the leading group and reference for PDX models in Belgium and is also a council member and active partner of the EuroPDX Consortium (www.europdx.eu), which allows the platform to be interactive on an international level.

Frédéric Amant, MD, PhD is a specialist in Gynaecological Oncology at the University Hospitals Leuven (UZ Leuven, Gasthuisberg), Belgium, and at Antoni van Leeuwenhoek – Netherlands Cancer Institute (Center for Gynaecological Oncology Amsterdam), the Netherlands. He is professor at the KU Leuven, Belgium, where he heads the scientific section of his speciality. In 2012, he obtained a grant from the National Cancer Plan which allowed him to start the Patient Derived Tumor Xenograft Platform, now Trace, at the KU Leuven, and he also heads the International Network on ‘Cancer, Infertility and Pregnancy (INCIP)’ of the European Society of Gynaecological Oncology (ESGO) (www.cancerinpregnancy.org). In the Hepamut project, Trace will be involved in the development of HCC-PDX models and testing of the efficacy of adoptive T cell therapy and monoclonal antibodies against relevant mutated proteins in HCC in these newly established HCC-PDX models.

[/vc_column_text][/vc_column][vc_column width=”1/6″][vc_single_image image=”260″ img_size=”full” alignment=”center” image_hovers=”false”][/vc_column][/vc_row][vc_row][vc_column]


1) Leucci E et al., Melanoma addiction to the lineage-restricted lncRNA SAMMSON. Nature – in press Jan 2016.

2) Hidalgo M, et al., Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research. Cancer Discov. 2014 Sep;4(9):998-1013. Epub 2014 Jul 15. Review.

3) Dewaele M et al., Antisense oligonucleotide-mediated MDM4 exon 6 skipping impairs tumor growth. J Clin Invest. 2016 Jan 4;126(1):68-84.

4) Radaelli E et al., Spontaneous Post-Transplant Disorders in NOD.Cg- Prkdcscid Il2rgtm1Sug/JicTac (NOG) Mice Engrafted with Patient-Derived Metastatic Melanomas. PLoS One. 2015 May 21;10 (5):e0124974.

5) Depreeuw J et al., Characterization of patient-derived tumor xenograft models of endometrial cancer for preclinical evaluation of targeted therapies. Gynecol Oncol. 2015 Oct;139(1):118-26.